BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30420593)

  • 1. Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma.
    Han JJ; O'byrne M; Stenson MJ; Maurer MJ; Wellik LE; Feldman AL; McPhail ED; Witzig TE; Gupta M
    Blood Cancer J; 2018 Nov; 8(11):110. PubMed ID: 30420593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphorylated STAT3 as a potential diagnostic and predictive biomarker in ALK
    Xiang C; Wu W; Fan M; Wang Z; Feng X; Liu C; Liu J; Liu G; Xia L; Si H; Gu Y; Liu N; Luo D; Wang Y; Ma D; Hu S; Liu H
    Front Immunol; 2023; 14():1132834. PubMed ID: 37388733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and prognostic implications of tumor expression of the GATA-3 gene in nodal peripheral T-cell lymphoma (nPTCL): Retrospective data from a Latin American cohort.
    de Pádua Covas Lage LA; Brito CV; Levy D; Culler HF; Freitas Couto SC; de Oliveira LBA; Nogueira Zerbini MC; Rocha V; Pereira J
    Leuk Res; 2022 Mar; 114():106794. PubMed ID: 35131666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.
    Han Y; Amin HM; Frantz C; Franko B; Lee J; Lin Q; Lai R
    Leukemia; 2006 Sep; 20(9):1602-9. PubMed ID: 16871283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dependence of peripheral T-cell lymphoma on constitutively activated JAK3: Implication for JAK3 inhibition as a therapeutic approach.
    Le K; Vollenweider J; Han J; Staudinger N; Stenson M; Bayraktar L; Wellik LE; Maurer MJ; McPhail ED; Witzig TE; Gupta M
    Hematol Oncol; 2024 Jan; 42(1):e3233. PubMed ID: 37876297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
    Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
    Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma.
    Han Y; Amin HM; Franko B; Frantz C; Shi X; Lai R
    Blood; 2006 Oct; 108(8):2796-803. PubMed ID: 16825495
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Andersson EI; Brück O; Braun T; Mannisto S; Saikko L; Lagström S; Ellonen P; Leppä S; Herling M; Kovanen PE; Mustjoki S
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32188095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of function mutations in PTPN6 promote STAT3 deregulation via JAK3 kinase in diffuse large B-cell lymphoma.
    Demosthenous C; Han JJ; Hu G; Stenson M; Gupta M
    Oncotarget; 2015 Dec; 6(42):44703-13. PubMed ID: 26565811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study.
    Piccaluga PP; Fuligni F; De Leo A; Bertuzzi C; Rossi M; Bacci F; Sabattini E; Agostinelli C; Gazzola A; Laginestra MA; Mannu C; Sapienza MR; Hartmann S; Hansmann ML; Piva R; Iqbal J; Chan JC; Weisenburger D; Vose JM; Bellei M; Federico M; Inghirami G; Zinzani PL; Pileri SA
    J Clin Oncol; 2013 Aug; 31(24):3019-25. PubMed ID: 23857971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified.
    ten Berge RL; de Bruin PC; Oudejans JJ; Ossenkoppele GJ; van der Valk P; Meijer CJ
    Histopathology; 2003 Nov; 43(5):462-9. PubMed ID: 14636272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma.
    Khoury JD; Medeiros LJ; Rassidakis GZ; Yared MA; Tsioli P; Leventaki V; Schmitt-Graeff A; Herling M; Amin HM; Lai R
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3692-9. PubMed ID: 14506160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High intratumoural galectin-1 expression predicts adverse outcome in ALK
    Holst JM; Ludvigsen M; Hamilton-Dutoit SJ; Bendix K; Plesner TL; Nørgaard P; Møller MB; Steiniche T; Rabinovich GA; d'Amore F; Pedersen MB
    Hematol Oncol; 2020 Feb; 38(1):59-66. PubMed ID: 31834627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
    Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
    J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum IgA level, monocyte count, and international prognostic index are independently associated with overall survival in patients with HTLV-I-negative nodal peripheral T cell lymphoma.
    Kato A; Imai Y; Aoki K; Tabata S; Matsushita A; Hashimoto H; Takahashi T; Ishikawa T
    Ann Hematol; 2014 Jul; 93(7):1185-91. PubMed ID: 24526138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetics of peripheral T-cell lymphomas.
    Piccaluga PP; Tabanelli V; Pileri SA
    Int J Hematol; 2014 Mar; 99(3):219-26. PubMed ID: 24481943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Jak3 activation is significantly associated with ALK expression in anaplastic large cell lymphoma.
    Lai R; Rassidakis GZ; Lin Q; Atwell C; Medeiros LJ; Amin HM
    Hum Pathol; 2005 Sep; 36(9):939-44. PubMed ID: 16153455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Lai R; Rassidakis GZ; Medeiros LJ; Ramdas L; Goy AH; Cutler C; Fujio Y; Kunisada K; Amin HM; Gilles F
    Am J Pathol; 2004 Jun; 164(6):2251-8. PubMed ID: 15161657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.
    Martín-Sánchez E; Odqvist L; Rodríguez-Pinilla SM; Sánchez-Beato M; Roncador G; Domínguez-González B; Blanco-Aparicio C; García Collazo AM; Cantalapiedra EG; Fernández JP; Curiel del Olmo S; Pisonero H; Madureira R; Almaraz C; Mollejo M; Alves FJ; Menárguez J; González-Palacios F; Rodríguez-Peralto JL; Ortiz-Romero PL; Real FX; García JF; Bischoff JR; Piris MA
    PLoS One; 2014; 9(11):e112148. PubMed ID: 25386922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified.
    Ludvigsen M; Bjerregård Pedersen M; Lystlund Lauridsen K; Svenstrup Poulsen T; Hamilton-Dutoit SJ; Besenbacher S; Bendix K; Møller MB; Nørgaard P; d'Amore F; Honoré B
    Blood Adv; 2018 Oct; 2(19):2533-2542. PubMed ID: 30291111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.